Chemomab Therapeutics Ltd. (CMMB)
NASDAQ: CMMB · Real-Time Price · USD
1.680
+0.060 (3.70%)
At close: Dec 20, 2024, 4:00 PM
1.640
-0.040 (-2.38%)
After-hours: Dec 20, 2024, 5:27 PM EST
Chemomab Therapeutics Employees
Chemomab Therapeutics had 20 employees as of December 31, 2021.
Employees
20
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$719,950
Market Cap
31.68M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2021 | 20 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Nortech Systems | 775 |
| Accelerate Diagnostics | 134 |
| RAPT Therapeutics | 131 |
| Beyond Air | 107 |
| OneMedNet | 20 |
| Tempest Therapeutics | 17 |
| Incannex Healthcare | 9 |
| RenovoRx | 8 |
CMMB News
- 18 days ago - Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit - GlobeNewsWire
- 4 weeks ago - Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis - GlobeNewsWire
- 4 months ago - Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update - GlobeNewsWire
- 5 months ago - Chemomab Therapeutics Announces Closing of $10 Million Private Placement - GlobeNewsWire
- 5 months ago - Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement - GlobeNewsWire
- 5 months ago - Chemomab Therapeutics Announces $10 Million Private Placement - GlobeNewsWire
- 5 months ago - Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis - GlobeNewsWire